ENDEAVOUR Lung Cancer Program Forms International Teams to Initiate Four Collaborative Projects Focused on Advancing Patient Care
MADRID--(BUSINESS WIRE)--The ENDEAVOUR lung cancer program, a three-year initiative designed to advance lung cancer research and care by connecting early-career oncologists in Europe with internationally renowned experts in thoracic oncology, has selected 21 participants to form international teams that will initiate four collaborative projects at the kick-off event in Madrid.
The projects to be developed over the next three years under expert guidance address critical unmet needs in lung cancer. The four selected research projects each focus on important challenges: two will investigate treatment resistance mechanisms—one in small cell lung cancer and one in non-small cell lung cancer—with the aim of better understanding the characteristics of these tumors and finding strategies to overcome this resistance. The third project will use artificial intelligence to analyze long-term responders to specific therapies, seeking to identify features that could guide future treatment decisions. The fourth project will concentrate on certain non-small cell lung cancer patients with brain metastases, a group known to have particularly poor prognoses, with the goal of uncovering key characteristics that could support more personalized therapeutic strategies.
'To be chosen among more than 20 projects — all led by passionate professionals asking meaningful questions in lung cancer — is a real honor,' says Dr. Edouard Auclin, Institut Bergonié, France. 'Each project brings valuable insights to the field. My project focuses on patients with high inflammation who tend to have poorer outcomes and are often underrepresented in clinical trials. By thinking outside the box, we aim to develop new approaches that could better address their needs and improve their treatment responses. I am truly happy to be part of this program and look forward to what we can accomplish together.' In addition to Dr. Auclin, the selected project leads are Dr. Marcel Kemper from University Hospital, Germany; Dr. Pedro Rocha from Hospital Vall d'Hebron, Spain; and Dr. Francesca Ogliari from IRCCS Scientific Institute and Hospital San Raffaele, Italy.
Fostering Excellence with Patient-Centric Purpose
Lung cancer is the most common cancer and the leading cause of cancer-related deaths worldwide. 1 Nearly 2.5 million lung cancer cases were diagnosed globally in 2022. 1 'Mentoring and fostering the next generation of thoracic oncologists is essential to sustaining scientific innovation and improving patient outcomes,' says Prof. Lizza Hendriks, Associate Professor at Maastricht University Medical Center, Maastricht, The Netherlands and ENDEAVOUR Lung Cancer Program Committee Member. 'Through this initiative, participants gain the tools and critical skills needed to become the lung cancer leaders of tomorrow to treat patients with the latest scientific knowledge. I was truly impressed and energized by the outstanding quality of applications received and look forward to the outcomes of the collaborations that will emerge from this program.'
While the participating oncologists deeply exchange about their research and clinical practice within the group, the goal of the program is to improve lung cancer care for patients and have a real-world impact.
'Every advance in cancer care begins with a single idea — and a deep commitment to patients,' says Dr. Michael Zaiac, Head of European Medical Affairs Oncology, Daiichi Sankyo. 'At Daiichi Sankyo, we believe that great patient care is fueled by both innovation and experience. ENDEAVOUR brings these elements together by connecting bright, early-career oncologists with seasoned experts, and providing the support needed to turn ideas into impact. We are proud to back a program that fosters scientific excellence while keeping patients at the center of every discovery.'
The ENDEAVOUR lung cancer program is guided by a distinguished steering committee of eight leading experts in thoracic oncology. Together, they are responsible for the independent design of the program, the selection of participants and the scientific mentorship provided throughout.
Prof. Lizza Hendriks, Maastricht University Medical Centre, Maastricht, The Netherlands
Prof. Pilar Garrido, Hospital Universitario Ramón y Cajal, Madrid, Spain
Prof. David Planchard, Institut Gustave Roussy, Villejuif, France
Prof. António Araújo, Centro Hospitalar Universitário do Porto, Porto, Portugal
Prof. Frank Griesinger, University Medicine Oldenburg, Pius-Hospital, Oldenburg, Germany
Prof. Andreas Pircher, Medical University of Innsbruck, Insbruck, Austria
Prof. Francesco Grossi, University of Insubria, Varese, Italy
Prof. Natasha Leighl, Princess Margaret Cancer Centre, Toronto, Canada
About the ENDEAVOUR Lung Program
The ENDEAVOUR programs are an initiative supported by Daiichi Sankyo, aimed at developing the next generation of oncology top experts across Europe by fostering scientific exchange and clinical practice sharing. Guided by a distinguished steering committee of leading oncology experts, the three-year programs are designed to promote excellence in research and enhance clinical knowledge to drive scientific innovation and improve patient outcomes. Building on the success of the ENDEAVOUR breast cancer program, the ENDEAVOUR lung cancer program will support 21 emerging lung cancer specialists from 2025 to 2027.
About Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit www.daiichi-sankyo.eu.
1 World Health Organization. International Agency for Research on Cancer. Lung Fact Sheet. Accessed July 2024.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, June 06, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and thereafter in equal portions upon the lapse of each three-month period over the following 36-month period, subject to the employee's continued employment with Neurogene through the applicable vesting dates. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit View source version on Contacts Company Contact: Cara MayfieldVice President, Corporate Investor Contact: Melissa ForstArgot PartnersNeurogene@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 hours ago
- Yahoo
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, June 06, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and thereafter in equal portions upon the lapse of each three-month period over the following 36-month period, subject to the employee's continued employment with Neurogene through the applicable vesting dates. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit View source version on Contacts Company Contact: Cara MayfieldVice President, Corporate Investor Contact: Melissa ForstArgot PartnersNeurogene@
Health Line
10 hours ago
- Health Line
Seeing a Psychiatrist for the First Time
At first, I was scared and overwhelmed by the thought of seeing a psychiatrist. The first psychiatric evaluation is, in my experience, the most intense and lengthy of your entrance into the world of seeing a psychiatrist. I've been going to the psychiatrist for over 5 years. Read on for more about my experience. Initial appointment My evaluation was in person with my doctor (in early 2020, pre-pandemic), and my partner also came along as a support person to provide his insight and answer questions as needed. My psychiatrist manages a mental health program at a hospital, and that's how I got connected with him for my first appointment. There are many ways to find a psychiatrist. Many psychiatrists do not take insurance, but some do. Your insurance may also reimburse you, if that's part of your plan. If you pay out of pocket, it can be expensive: I've been quoted anywhere from $400+ for the initial intake. Follow-up appointments are usually cheaper, but still cost at least $100 each. Some specialty mental health programs receive grants that may make the appointments more affordable. Ahead of the appointment, you might be asked to complete a questionnaire to help your psychiatrist evaluate your symptoms. The questionnaires are usually about anxiety, depression, and more. You'll also provide your family medical history, or what you know of it. Completing the questionnaires may feel overwhelming, so it's a good idea take breaks as you work your way through them, if you are able. It may also feel scary. For me, I worried that the psychiatrist was going to discover a new diagnosis that I had not already been given. That's probably a typical trauma response: 'What is wrong with me? Am I broken? Will I always feel like this?' were all thoughts that I had when initially accepting that I needed a psychiatrist for my mental healthcare. My first appointment was close to an hour long and involved a long conversation with my doctor. I felt mentally drained and exhausted afterward, so I rested for the afternoon. A few years later, I can say that having a psychiatrist whom I trust has made all the difference in my ability to care for myself and my mental health. Follow-up appointments Follow-ups tend to be shorter, at about 30 minutes or less, depending on how you're feeling. My psychiatrist and I chat about my mood and the potential side effects of the medications. We discuss how things are going in my life, including work, socialization, exercise, sleep, hobbies, energy levels, and more. It's not a therapy appointment, but more like a check-in about overall wellness. Then, we discuss any potential medication modifications, and my psychiatrist answers questions that I may have. Appointment frequency with your psychiatrist will vary based on your care. Follow-ups with my psychiatrist are more routine now; I go four times a year. It's important to meet with them periodically, as needed, depending on how you're doing. If I've made a medication change, whether switching to a different medication or upping or lowering a dose, I'll meet with them more frequently to check in. I now meet with my psychiatrist via video, using an app the hospital system utilizes for secure connection.
